Abstract 3039: Pediatric preclinical testing consortium evaluation of the dual SYK/FLT3 inhibitor TAK-659 in xenograft models of pediatric acute lymphoblastic leukemia
Sign Up to like & getrecommendations! Published in 2021 at "Tumor Biology"
DOI: 10.1158/1538-7445.am2021-3039
Abstract: Introduction: While children with acute lymphoblastic leukemia (ALL) experience close to a 90% likelihood of cure, the outcome for certain high-risk pediatric ALL subtypes remains poor. Spleen Tyrosine Kinase (SYK), a cytosolic nonreceptor tyrosine kinase,… read more here.
Keywords: leukemia; lineage; tak 659; syk flt3 ... See more keywords
Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts
Sign Up to like & getrecommendations! Published in 2023 at "PLOS ONE"
DOI: 10.1371/journal.pone.0282177
Abstract: There are currently no clinical strategies utilizing tumor gene expression to inform therapeutic selection for patients with head and neck squamous cell carcinoma (HNSCC). One of the challenges in developing predictive biomarkers is the limited… read more here.
Keywords: head neck; derived xenografts; pdxs; hnscc ... See more keywords
Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.930731
Abstract: Background Muscle-invasive bladder cancer (MIBC) and upper urinary tract urothelial carcinoma (UTUC) are molecularly heterogeneous. Despite chemotherapies, immunotherapies or anti-FGFR treatments, these tumors are still of poor outcome. Our objective was to develop a bank… read more here.
Keywords: derived xenografts; pharmacological characterization; pdxs; patient ... See more keywords